NO312134B1 - Tiazolderivater, fremgangsmåte for fremstilling og anvendelse av dem, farmasöytisk preparat inneholdende dem og mellomprodukteri fremstillingen - Google Patents
Tiazolderivater, fremgangsmåte for fremstilling og anvendelse av dem, farmasöytisk preparat inneholdende dem og mellomprodukteri fremstillingen Download PDFInfo
- Publication number
- NO312134B1 NO312134B1 NO19986160A NO986160A NO312134B1 NO 312134 B1 NO312134 B1 NO 312134B1 NO 19986160 A NO19986160 A NO 19986160A NO 986160 A NO986160 A NO 986160A NO 312134 B1 NO312134 B1 NO 312134B1
- Authority
- NO
- Norway
- Prior art keywords
- carbonyl
- guanidino
- ylmethoxy
- piperidin
- ethyl
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 24
- 238000004519 manufacturing process Methods 0.000 title claims description 9
- 238000002360 preparation method Methods 0.000 title description 6
- 239000000543 intermediate Substances 0.000 title description 3
- 150000007979 thiazole derivatives Chemical class 0.000 title description 3
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims description 62
- 150000002148 esters Chemical class 0.000 claims description 32
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 25
- 150000003839 salts Chemical class 0.000 claims description 23
- 239000000203 mixture Substances 0.000 claims description 21
- 239000002253 acid Substances 0.000 claims description 14
- 206010028980 Neoplasm Diseases 0.000 claims description 12
- 102100022337 Integrin alpha-V Human genes 0.000 claims description 11
- 108010048673 Vitronectin Receptors Proteins 0.000 claims description 11
- 239000001257 hydrogen Substances 0.000 claims description 11
- 229910052739 hydrogen Inorganic materials 0.000 claims description 11
- 239000003814 drug Substances 0.000 claims description 10
- 150000001412 amines Chemical class 0.000 claims description 9
- 230000027455 binding Effects 0.000 claims description 9
- 102000004169 proteins and genes Human genes 0.000 claims description 9
- 108090000623 proteins and genes Proteins 0.000 claims description 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 8
- 201000010099 disease Diseases 0.000 claims description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 8
- 229940079593 drug Drugs 0.000 claims description 8
- 230000002792 vascular Effects 0.000 claims description 8
- 241000700605 Viruses Species 0.000 claims description 7
- 239000000853 adhesive Substances 0.000 claims description 7
- 230000001070 adhesive effect Effects 0.000 claims description 7
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 7
- 238000011321 prophylaxis Methods 0.000 claims description 7
- IJVLVRYLIMQVDD-UHFFFAOYSA-N 1,3-thiazole-2-carboxylic acid Chemical compound OC(=O)C1=NC=CS1 IJVLVRYLIMQVDD-UHFFFAOYSA-N 0.000 claims description 6
- 241000894006 Bacteria Species 0.000 claims description 6
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 6
- 206010027476 Metastases Diseases 0.000 claims description 6
- 208000001132 Osteoporosis Diseases 0.000 claims description 6
- 201000004681 Psoriasis Diseases 0.000 claims description 6
- 208000001647 Renal Insufficiency Diseases 0.000 claims description 6
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical group C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 claims description 6
- 206010003246 arthritis Diseases 0.000 claims description 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 6
- 208000015181 infectious disease Diseases 0.000 claims description 6
- 201000006370 kidney failure Diseases 0.000 claims description 6
- 208000002780 macular degeneration Diseases 0.000 claims description 6
- 239000000825 pharmaceutical preparation Substances 0.000 claims description 6
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 6
- 208000037803 restenosis Diseases 0.000 claims description 6
- 238000011282 treatment Methods 0.000 claims description 6
- 241000233866 Fungi Species 0.000 claims description 5
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 4
- 150000007513 acids Chemical class 0.000 claims description 4
- 230000009401 metastasis Effects 0.000 claims description 4
- PAXRRXXEJKKKRE-UHFFFAOYSA-N 2-[[1-[2-(diaminomethylideneamino)-4-phenyl-1,3-thiazole-5-carbonyl]piperidin-3-yl]methoxy]acetic acid Chemical compound S1C(NC(=N)N)=NC(C=2C=CC=CC=2)=C1C(=O)N1CCCC(COCC(O)=O)C1 PAXRRXXEJKKKRE-UHFFFAOYSA-N 0.000 claims description 3
- OQFFJRXPVGFSSN-UHFFFAOYSA-N 2-[[1-[2-(diaminomethylideneamino)-4-propyl-1,3-thiazole-5-carbonyl]piperidin-3-yl]methoxy]acetic acid Chemical compound N1=C(NC(N)=N)SC(C(=O)N2CC(COCC(O)=O)CCC2)=C1CCC OQFFJRXPVGFSSN-UHFFFAOYSA-N 0.000 claims description 3
- NXWNWIUJZFUZLH-UHFFFAOYSA-N 2-[[1-[4-tert-butyl-2-(diaminomethylideneamino)-1,3-thiazole-5-carbonyl]piperidin-3-yl]methoxy]acetic acid Chemical compound N1=C(NC(N)=N)SC(C(=O)N2CC(COCC(O)=O)CCC2)=C1C(C)(C)C NXWNWIUJZFUZLH-UHFFFAOYSA-N 0.000 claims description 3
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical group C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 2
- 239000003146 anticoagulant agent Substances 0.000 claims description 2
- 229940127219 anticoagulant drug Drugs 0.000 claims description 2
- 230000003480 fibrinolytic effect Effects 0.000 claims description 2
- 150000002431 hydrogen Chemical class 0.000 claims description 2
- 230000007257 malfunction Effects 0.000 claims description 2
- 125000005936 piperidyl group Chemical group 0.000 claims description 2
- 239000000106 platelet aggregation inhibitor Substances 0.000 claims description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims description 2
- 229940124597 therapeutic agent Drugs 0.000 claims description 2
- 238000002560 therapeutic procedure Methods 0.000 claims description 2
- ANPXJLVOAXTPRP-SECBINFHSA-N 2-[[(3r)-1-[2-(diaminomethylideneamino)-4-methyl-1,3-thiazole-5-carbonyl]piperidin-3-yl]methoxy]acetic acid Chemical compound N1=C(NC(N)=N)SC(C(=O)N2C[C@H](COCC(O)=O)CCC2)=C1C ANPXJLVOAXTPRP-SECBINFHSA-N 0.000 claims 1
- QGXYFSBQMTYCRZ-UHFFFAOYSA-N 2-[[1-[4-cyclopentyl-2-(diaminomethylideneamino)-1,3-thiazole-5-carbonyl]piperidin-3-yl]methoxy]acetic acid Chemical compound C1CCC(COCC(O)=O)CN1C(=O)C=1SC(NC(=N)N)=NC=1C1CCCC1 QGXYFSBQMTYCRZ-UHFFFAOYSA-N 0.000 claims 1
- 239000002023 wood Substances 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 44
- -1 dimethyl-cyclopropyl Chemical group 0.000 description 38
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 35
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 34
- 239000000243 solution Substances 0.000 description 30
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 28
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 27
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 22
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 21
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 16
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 13
- 239000011541 reaction mixture Substances 0.000 description 13
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 12
- 239000000047 product Substances 0.000 description 11
- 239000002904 solvent Substances 0.000 description 11
- 239000000872 buffer Substances 0.000 description 10
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 9
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- 239000002585 base Substances 0.000 description 9
- 230000008878 coupling Effects 0.000 description 9
- 238000010168 coupling process Methods 0.000 description 9
- 238000005859 coupling reaction Methods 0.000 description 9
- 239000006260 foam Substances 0.000 description 8
- 125000001424 substituent group Chemical group 0.000 description 8
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 8
- OJOGDTMEXJQOQA-UHFFFAOYSA-N 2-(diaminomethylideneamino)-4-methyl-1,3-thiazole-5-carboxylic acid Chemical compound CC=1N=C(NC(N)=N)SC=1C(O)=O OJOGDTMEXJQOQA-UHFFFAOYSA-N 0.000 description 7
- 108010049003 Fibrinogen Proteins 0.000 description 7
- 102000008946 Fibrinogen Human genes 0.000 description 7
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 7
- RROBIDXNTUAHFW-UHFFFAOYSA-N benzotriazol-1-yloxy-tris(dimethylamino)phosphanium Chemical compound C1=CC=C2N(O[P+](N(C)C)(N(C)C)N(C)C)N=NC2=C1 RROBIDXNTUAHFW-UHFFFAOYSA-N 0.000 description 7
- 229940012952 fibrinogen Drugs 0.000 description 7
- 239000011780 sodium chloride Substances 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 6
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- ZQBSUHOFZPUSGW-UHFFFAOYSA-N ethyl 2-(piperidin-3-ylmethoxy)acetate;hydrochloride Chemical compound Cl.CCOC(=O)COCC1CCCNC1 ZQBSUHOFZPUSGW-UHFFFAOYSA-N 0.000 description 6
- 239000012071 phase Substances 0.000 description 6
- NNRFRJQMBSBXGO-CIUDSAMLSA-N (3s)-3-[[2-[[(2s)-2-amino-5-(diaminomethylideneamino)pentanoyl]amino]acetyl]amino]-4-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-oxobutanoic acid Chemical compound NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CO)C(O)=O NNRFRJQMBSBXGO-CIUDSAMLSA-N 0.000 description 5
- GPIQOFWTZXXOOV-UHFFFAOYSA-N 2-chloro-4,6-dimethoxy-1,3,5-triazine Chemical compound COC1=NC(Cl)=NC(OC)=N1 GPIQOFWTZXXOOV-UHFFFAOYSA-N 0.000 description 5
- 125000000217 alkyl group Chemical group 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- XMIIGOLPHOKFCH-UHFFFAOYSA-N 3-phenylpropionic acid Chemical compound OC(=O)CCC1=CC=CC=C1 XMIIGOLPHOKFCH-UHFFFAOYSA-N 0.000 description 4
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 4
- 101000829980 Homo sapiens Ral guanine nucleotide dissociation stimulator Proteins 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 102100023320 Ral guanine nucleotide dissociation stimulator Human genes 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 238000003776 cleavage reaction Methods 0.000 description 4
- AYKYVVQCWGHYET-UHFFFAOYSA-N ethyl 3-(piperidine-3-carbonylamino)propanoate;hydrochloride Chemical compound Cl.CCOC(=O)CCNC(=O)C1CCCNC1 AYKYVVQCWGHYET-UHFFFAOYSA-N 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 230000008020 evaporation Effects 0.000 description 4
- 239000007903 gelatin capsule Substances 0.000 description 4
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 229920005862 polyol Polymers 0.000 description 4
- 150000003077 polyols Chemical class 0.000 description 4
- 238000007127 saponification reaction Methods 0.000 description 4
- 230000007017 scission Effects 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- OJCLHERKFHHUTB-UHFFFAOYSA-N tert-butyl 3-(hydroxymethyl)piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCC(CO)C1 OJCLHERKFHHUTB-UHFFFAOYSA-N 0.000 description 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- NXILIHONWRXHFA-UHFFFAOYSA-N 1-[(2-methylpropan-2-yl)oxycarbonyl]piperidine-3-carboxylic acid Chemical compound CC(C)(C)OC(=O)N1CCCC(C(O)=O)C1 NXILIHONWRXHFA-UHFFFAOYSA-N 0.000 description 3
- ANPXJLVOAXTPRP-UHFFFAOYSA-N 2-[[1-[2-(diaminomethylideneamino)-4-methyl-1,3-thiazole-5-carbonyl]piperidin-3-yl]methoxy]acetic acid Chemical compound N1=C(NC(N)=N)SC(C(=O)N2CC(COCC(O)=O)CCC2)=C1C ANPXJLVOAXTPRP-UHFFFAOYSA-N 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 3
- HVCNXQOWACZAFN-UHFFFAOYSA-N 4-ethylmorpholine Chemical compound CCN1CCOCC1 HVCNXQOWACZAFN-UHFFFAOYSA-N 0.000 description 3
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 3
- WPIOJZJXSKLRNF-UHFFFAOYSA-N Cl.C=1C=CC=CC=1C(CC(=O)OCC)NC(=O)C1CCCNC1 Chemical compound Cl.C=1C=CC=CC=1C(CC(=O)OCC)NC(=O)C1CCCNC1 WPIOJZJXSKLRNF-UHFFFAOYSA-N 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 108010067306 Fibronectins Proteins 0.000 description 3
- 102000016359 Fibronectins Human genes 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 229920004890 Triton X-100 Polymers 0.000 description 3
- 239000013504 Triton X-100 Substances 0.000 description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 3
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 3
- 239000001110 calcium chloride Substances 0.000 description 3
- 235000011148 calcium chloride Nutrition 0.000 description 3
- 229910001628 calcium chloride Inorganic materials 0.000 description 3
- 230000008619 cell matrix interaction Effects 0.000 description 3
- 239000008298 dragée Substances 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 230000032050 esterification Effects 0.000 description 3
- 238000005886 esterification reaction Methods 0.000 description 3
- KQWWVLVLVYYYDT-UHFFFAOYSA-N ethyl 3-oxohexanoate Chemical compound CCCC(=O)CC(=O)OCC KQWWVLVLVYYYDT-UHFFFAOYSA-N 0.000 description 3
- PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000005984 hydrogenation reaction Methods 0.000 description 3
- 230000008611 intercellular interaction Effects 0.000 description 3
- 239000013067 intermediate product Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000012074 organic phase Substances 0.000 description 3
- 210000002826 placenta Anatomy 0.000 description 3
- 239000002464 receptor antagonist Substances 0.000 description 3
- 229940044551 receptor antagonist Drugs 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- GIYKXTTUGRGLQC-SECBINFHSA-N tert-butyl 2-[[(3r)-pyrrolidin-3-yl]methoxy]acetate Chemical compound CC(C)(C)OC(=O)COC[C@@H]1CCNC1 GIYKXTTUGRGLQC-SECBINFHSA-N 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- AWNXKZVIZARMME-UHFFFAOYSA-N 1-[[5-[2-[(2-chloropyridin-4-yl)amino]pyrimidin-4-yl]-4-(cyclopropylmethyl)pyrimidin-2-yl]amino]-2-methylpropan-2-ol Chemical compound N=1C(NCC(C)(O)C)=NC=C(C=2N=C(NC=3C=C(Cl)N=CC=3)N=CC=2)C=1CC1CC1 AWNXKZVIZARMME-UHFFFAOYSA-N 0.000 description 2
- HCBSWIVRSZSOCA-UHFFFAOYSA-N 2-(benzylcarbamoylamino)-4-methyl-1,3-thiazole-5-carboxylic acid Chemical compound S1C(C(O)=O)=C(C)N=C1NC(=O)NCC1=CC=CC=C1 HCBSWIVRSZSOCA-UHFFFAOYSA-N 0.000 description 2
- FHYKCQRCKSUZGL-UHFFFAOYSA-N 2-(diaminomethylideneamino)-1,3-thiazole-5-carboxylic acid Chemical compound NC(=N)NC1=NC=C(C(O)=O)S1 FHYKCQRCKSUZGL-UHFFFAOYSA-N 0.000 description 2
- IRZHUMRBBAVGOA-UHFFFAOYSA-N 2-(diaminomethylideneamino)-4-phenyl-1,3-thiazole-5-carboxylic acid Chemical compound S1C(NC(=N)N)=NC(C=2C=CC=CC=2)=C1C(O)=O IRZHUMRBBAVGOA-UHFFFAOYSA-N 0.000 description 2
- RLWFSZLVYWBFLQ-UHFFFAOYSA-N 2-(diaminomethylideneamino)-4-propyl-1,3-thiazole-5-carboxylic acid;hydrochloride Chemical compound Cl.CCCC=1N=C(NC(N)=N)SC=1C(O)=O RLWFSZLVYWBFLQ-UHFFFAOYSA-N 0.000 description 2
- GLJFUACWSFBDNA-SNVBAGLBSA-N 2-[[(3R)-1-[(2-methylpropan-2-yl)oxycarbonyl]piperidin-3-yl]methoxy]acetic acid Chemical compound CC(C)(C)OC(=O)N1CCC[C@@H](COCC(O)=O)C1 GLJFUACWSFBDNA-SNVBAGLBSA-N 0.000 description 2
- GLJFUACWSFBDNA-JTQLQIEISA-N 2-[[(3S)-1-[(2-methylpropan-2-yl)oxycarbonyl]piperidin-3-yl]methoxy]acetic acid Chemical compound CC(C)(C)OC(=O)N1CCC[C@H](COCC(O)=O)C1 GLJFUACWSFBDNA-JTQLQIEISA-N 0.000 description 2
- GLJFUACWSFBDNA-UHFFFAOYSA-N 2-[[1-[(2-methylpropan-2-yl)oxycarbonyl]piperidin-3-yl]methoxy]acetic acid Chemical compound CC(C)(C)OC(=O)N1CCCC(COCC(O)=O)C1 GLJFUACWSFBDNA-UHFFFAOYSA-N 0.000 description 2
- WFWASNZJDVYFDB-UHFFFAOYSA-N 4-cyclopentyl-2-(diaminomethylideneamino)-1,3-thiazole-5-carboxylic acid;hydrochloride Chemical compound Cl.S1C(NC(=N)N)=NC(C2CCCC2)=C1C(O)=O WFWASNZJDVYFDB-UHFFFAOYSA-N 0.000 description 2
- TXXIWXPZBIXLRT-UHFFFAOYSA-N 4-methyl-2-(methylcarbamoylamino)-1,3-thiazole-5-carboxylic acid Chemical compound CNC(=O)NC1=NC(C)=C(C(O)=O)S1 TXXIWXPZBIXLRT-UHFFFAOYSA-N 0.000 description 2
- YDZUUHATPNSARU-UHFFFAOYSA-N 4-tert-butyl-2-(diaminomethylideneamino)-1,3-thiazole-5-carboxylic acid;hydrochloride Chemical compound Cl.CC(C)(C)C=1N=C(NC(N)=N)SC=1C(O)=O YDZUUHATPNSARU-UHFFFAOYSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 2
- GXPIBOVZNZUEMW-CVEARBPZSA-N C1(=CC=CC=C1)[C@@H](C)N1C[C@H](CC1)COCC(=O)OC(C)(C)C Chemical compound C1(=CC=CC=C1)[C@@H](C)N1C[C@H](CC1)COCC(=O)OC(C)(C)C GXPIBOVZNZUEMW-CVEARBPZSA-N 0.000 description 2
- KXDHJXZQYSOELW-UHFFFAOYSA-N Carbamic acid Chemical compound NC(O)=O KXDHJXZQYSOELW-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 108010012088 Fibrinogen Receptors Proteins 0.000 description 2
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 102000004264 Osteopontin Human genes 0.000 description 2
- 108010081689 Osteopontin Proteins 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 239000007983 Tris buffer Substances 0.000 description 2
- 108010031318 Vitronectin Proteins 0.000 description 2
- 102100035140 Vitronectin Human genes 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 125000003710 aryl alkyl group Chemical group 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 229940098773 bovine serum albumin Drugs 0.000 description 2
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 2
- 229910052794 bromium Inorganic materials 0.000 description 2
- 239000007853 buffer solution Substances 0.000 description 2
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- MOIPGXQKZSZOQX-UHFFFAOYSA-N carbonyl bromide Chemical compound BrC(Br)=O MOIPGXQKZSZOQX-UHFFFAOYSA-N 0.000 description 2
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
- 239000003054 catalyst Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- VPMRGFCOSZORMN-UHFFFAOYSA-N ethyl 2-(benzylcarbamoylamino)-4-methyl-1,3-thiazole-5-carboxylate Chemical compound CC1=C(C(=O)OCC)SC(NC(=O)NCC=2C=CC=CC=2)=N1 VPMRGFCOSZORMN-UHFFFAOYSA-N 0.000 description 2
- IIZWYNDWOXSKNC-UHFFFAOYSA-N ethyl 2-(diaminomethylideneamino)-4-methyl-1,3-thiazole-5-carboxylate;hydrochloride Chemical compound Cl.CCOC(=O)C=1SC(NC(N)=N)=NC=1C IIZWYNDWOXSKNC-UHFFFAOYSA-N 0.000 description 2
- QGHZWHGVXLIALP-UHFFFAOYSA-N ethyl 2-(diaminomethylideneamino)-4-phenyl-1,3-thiazole-5-carboxylate;hydrobromide Chemical compound Br.S1C(NC(N)=N)=NC(C=2C=CC=CC=2)=C1C(=O)OCC QGHZWHGVXLIALP-UHFFFAOYSA-N 0.000 description 2
- FUIRJYVCEQYVMH-UHFFFAOYSA-N ethyl 2-(diaminomethylideneamino)-4-propyl-1,3-thiazole-5-carboxylate;hydrobromide Chemical compound Br.CCCC=1N=C(NC(N)=N)SC=1C(=O)OCC FUIRJYVCEQYVMH-UHFFFAOYSA-N 0.000 description 2
- KJYXFUVHYMVEMB-UHFFFAOYSA-N ethyl 2-(piperidin-4-ylmethoxy)acetate Chemical compound CCOC(=O)COCC1CCNCC1 KJYXFUVHYMVEMB-UHFFFAOYSA-N 0.000 description 2
- RFGKAPSZSFHNMI-UHFFFAOYSA-N ethyl 2-[[1-[2-(diaminomethylideneamino)-4-methyl-1,3-thiazole-5-carbonyl]piperidin-4-yl]methoxy]acetate Chemical compound C1CC(COCC(=O)OCC)CCN1C(=O)C1=C(C)N=C(N=C(N)N)S1 RFGKAPSZSFHNMI-UHFFFAOYSA-N 0.000 description 2
- ARFLASKVLJTEJD-UHFFFAOYSA-N ethyl 2-bromopropanoate Chemical compound CCOC(=O)C(C)Br ARFLASKVLJTEJD-UHFFFAOYSA-N 0.000 description 2
- ZNGYHCUWLDXODQ-UHFFFAOYSA-N ethyl 3-[[1-[2-(diaminomethylideneamino)-4-methyl-1,3-thiazole-5-carbonyl]piperidine-3-carbonyl]amino]propanoate Chemical compound C1C(C(=O)NCCC(=O)OCC)CCCN1C(=O)C1=C(C)N=C(NC(N)=N)S1 ZNGYHCUWLDXODQ-UHFFFAOYSA-N 0.000 description 2
- VUYNTIDSHCJIKF-UHFFFAOYSA-N ethyl 4,4-dimethyl-3-oxopentanoate Chemical compound CCOC(=O)CC(=O)C(C)(C)C VUYNTIDSHCJIKF-UHFFFAOYSA-N 0.000 description 2
- 125000004494 ethyl ester group Chemical group 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 2
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- YDNLNVZZTACNJX-UHFFFAOYSA-N isocyanatomethylbenzene Chemical compound O=C=NCC1=CC=CC=C1 YDNLNVZZTACNJX-UHFFFAOYSA-N 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 description 2
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 2
- 230000009871 nonspecific binding Effects 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 102000013415 peroxidase activity proteins Human genes 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 239000001120 potassium sulphate Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 238000005245 sintering Methods 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 229910052938 sodium sulfate Inorganic materials 0.000 description 2
- 235000011152 sodium sulphate Nutrition 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- GXPIBOVZNZUEMW-HZPDHXFCSA-N tert-butyl 2-[[(3r)-1-[(1r)-1-phenylethyl]pyrrolidin-3-yl]methoxy]acetate Chemical compound N1([C@H](C)C=2C=CC=CC=2)CC[C@@H](COCC(=O)OC(C)(C)C)C1 GXPIBOVZNZUEMW-HZPDHXFCSA-N 0.000 description 2
- LPWLXVDDRMCHNL-NSHDSACASA-N tert-butyl 2-[[(3s)-1-[2-(diaminomethylideneamino)-4-methyl-1,3-thiazole-5-carbonyl]pyrrolidin-3-yl]methoxy]acetate Chemical compound N1=C(NC(N)=N)SC(C(=O)N2C[C@@H](COCC(=O)OC(C)(C)C)CC2)=C1C LPWLXVDDRMCHNL-NSHDSACASA-N 0.000 description 2
- GIYKXTTUGRGLQC-VIFPVBQESA-N tert-butyl 2-[[(3s)-pyrrolidin-3-yl]methoxy]acetate Chemical compound CC(C)(C)OC(=O)COC[C@H]1CCNC1 GIYKXTTUGRGLQC-VIFPVBQESA-N 0.000 description 2
- DPCRBSLFBNIGLU-UHFFFAOYSA-N tert-butyl 3-[(3-ethoxy-3-oxopropyl)carbamoyl]piperidine-1-carboxylate Chemical compound CCOC(=O)CCNC(=O)C1CCCN(C(=O)OC(C)(C)C)C1 DPCRBSLFBNIGLU-UHFFFAOYSA-N 0.000 description 2
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 150000003585 thioureas Chemical class 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 108010047303 von Willebrand Factor Proteins 0.000 description 2
- 102100036537 von Willebrand factor Human genes 0.000 description 2
- 229960001134 von willebrand factor Drugs 0.000 description 2
- 239000001993 wax Substances 0.000 description 2
- ZTOJFFHGPLIVKC-YAFCTCPESA-N (2e)-3-ethyl-2-[(z)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound S\1C2=CC(S(O)(=O)=O)=CC=C2N(CC)C/1=N/N=C1/SC2=CC(S(O)(=O)=O)=CC=C2N1CC ZTOJFFHGPLIVKC-YAFCTCPESA-N 0.000 description 1
- AUYBSFAHQLKXSW-UHFFFAOYSA-N 1,2-dichloroethane;3-(ethyliminomethylideneamino)-n,n-dimethylpropan-1-amine;hydrochloride Chemical compound Cl.ClCCCl.CCN=C=NCCCN(C)C AUYBSFAHQLKXSW-UHFFFAOYSA-N 0.000 description 1
- HMVYYTRDXNKRBQ-UHFFFAOYSA-N 1,3-thiazole-4-carboxylic acid Chemical class OC(=O)C1=CSC=N1 HMVYYTRDXNKRBQ-UHFFFAOYSA-N 0.000 description 1
- YZVFSQQHQPPKNX-UHFFFAOYSA-N 1,3-thiazole-5-carboxylic acid Chemical class OC(=O)C1=CN=CS1 YZVFSQQHQPPKNX-UHFFFAOYSA-N 0.000 description 1
- DNUTZBZXLPWRJG-UHFFFAOYSA-N 1-Piperidine carboxylic acid Chemical compound OC(=O)N1CCCCC1 DNUTZBZXLPWRJG-UHFFFAOYSA-N 0.000 description 1
- HBOMLICNUCNMMY-KJFJCRTCSA-N 1-[(4s,5s)-4-azido-5-(hydroxymethyl)oxolan-2-yl]-5-methylpyrimidine-2,4-dione Chemical compound O=C1NC(=O)C(C)=CN1C1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-KJFJCRTCSA-N 0.000 description 1
- BJBMDOUDXXJCBS-UHFFFAOYSA-N 2-(carboxymethoxymethyl)pyrrolidine-1-carboxylic acid Chemical compound OC(=O)COCC1CCCN1C(O)=O BJBMDOUDXXJCBS-UHFFFAOYSA-N 0.000 description 1
- PIZACUWUMBNFFK-UHFFFAOYSA-N 2-(diaminomethylideneamino)-1,3-thiazole-4-carboxylic acid;hydrochloride Chemical compound Cl.NC(=N)NC1=NC(C(O)=O)=CS1 PIZACUWUMBNFFK-UHFFFAOYSA-N 0.000 description 1
- PVXYECAEDGMJNP-UHFFFAOYSA-N 2-(morpholin-2-ylmethoxy)acetic acid;hydrochloride Chemical compound Cl.OC(=O)COCC1CNCCO1 PVXYECAEDGMJNP-UHFFFAOYSA-N 0.000 description 1
- XBRTWUIFHFTUKK-UHFFFAOYSA-N 2-(pyridin-2-ylmethoxy)acetic acid Chemical compound OC(=O)COCC1=CC=CC=N1 XBRTWUIFHFTUKK-UHFFFAOYSA-N 0.000 description 1
- NHAFAQKGBMCEPF-UHFFFAOYSA-N 2-(pyridin-4-ylmethoxy)acetic acid Chemical compound OC(=O)COCC1=CC=NC=C1 NHAFAQKGBMCEPF-UHFFFAOYSA-N 0.000 description 1
- XSZDSKVYRROEJV-UHFFFAOYSA-N 2-[(4-benzylmorpholin-2-yl)methoxy]acetic acid Chemical compound C1COC(COCC(=O)O)CN1CC1=CC=CC=C1 XSZDSKVYRROEJV-UHFFFAOYSA-N 0.000 description 1
- YYLYNLCAWXUCDY-UHFFFAOYSA-N 2-[1-[(2-methylpropan-2-yl)oxycarbonyl]piperidin-3-yl]oxyacetic acid Chemical compound CC(C)(C)OC(=O)N1CCCC(OCC(O)=O)C1 YYLYNLCAWXUCDY-UHFFFAOYSA-N 0.000 description 1
- JGJFWWXRARLVKP-UHFFFAOYSA-N 2-[1-[2-(diaminomethylideneamino)-4-methyl-1,3-thiazole-5-carbonyl]piperidin-3-yl]oxyacetic acid Chemical compound N1=C(NC(N)=N)SC(C(=O)N2CC(CCC2)OCC(O)=O)=C1C JGJFWWXRARLVKP-UHFFFAOYSA-N 0.000 description 1
- REFAZLZHUMKSQM-UHFFFAOYSA-N 2-[1-[2-(diaminomethylideneamino)-4-methyl-1,3-thiazole-5-carbonyl]piperidin-4-yl]oxyacetic acid;2,2,2-trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.N1=C(N=C(N)N)SC(C(=O)N2CCC(CC2)OCC(O)=O)=C1C REFAZLZHUMKSQM-UHFFFAOYSA-N 0.000 description 1
- AEHSUOCPKSZMLF-MRVPVSSYSA-N 2-[[(3r)-1-[2-(diaminomethylideneamino)-4-methyl-1,3-thiazole-5-carbonyl]pyrrolidin-3-yl]methoxy]acetic acid Chemical compound N1=C(NC(N)=N)SC(C(=O)N2C[C@H](COCC(O)=O)CC2)=C1C AEHSUOCPKSZMLF-MRVPVSSYSA-N 0.000 description 1
- ANPXJLVOAXTPRP-VIFPVBQESA-N 2-[[(3s)-1-[2-(diaminomethylideneamino)-4-methyl-1,3-thiazole-5-carbonyl]piperidin-3-yl]methoxy]acetic acid Chemical compound N1=C(NC(N)=N)SC(C(=O)N2C[C@@H](COCC(O)=O)CCC2)=C1C ANPXJLVOAXTPRP-VIFPVBQESA-N 0.000 description 1
- AEHSUOCPKSZMLF-QMMMGPOBSA-N 2-[[(3s)-1-[2-(diaminomethylideneamino)-4-methyl-1,3-thiazole-5-carbonyl]pyrrolidin-3-yl]methoxy]acetic acid Chemical compound N1=C(NC(N)=N)SC(C(=O)N2C[C@@H](COCC(O)=O)CC2)=C1C AEHSUOCPKSZMLF-QMMMGPOBSA-N 0.000 description 1
- LXXMRJSJFZZOHU-UHFFFAOYSA-N 2-[[1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidin-2-yl]methoxy]acetic acid Chemical compound CC(C)(C)OC(=O)N1CCCC1COCC(O)=O LXXMRJSJFZZOHU-UHFFFAOYSA-N 0.000 description 1
- AUTZMBMZNXCBIS-UHFFFAOYSA-N 2-[[1-[2-(benzylcarbamoylamino)-4-methyl-1,3-thiazole-5-carbonyl]piperidin-3-yl]methoxy]acetic acid Chemical compound S1C(C(=O)N2CC(COCC(O)=O)CCC2)=C(C)N=C1NC(=O)NCC1=CC=CC=C1 AUTZMBMZNXCBIS-UHFFFAOYSA-N 0.000 description 1
- RAOCHKWZUGIUSL-UHFFFAOYSA-N 2-[[1-[2-(diaminomethylideneamino)-1,3-thiazole-4-carbonyl]piperidin-3-yl]methoxy]acetic acid Chemical compound S1C(NC(=N)N)=NC(C(=O)N2CC(COCC(O)=O)CCC2)=C1 RAOCHKWZUGIUSL-UHFFFAOYSA-N 0.000 description 1
- CMPHFAPVSQDBBX-UHFFFAOYSA-N 2-[[1-[2-(diaminomethylideneamino)-1,3-thiazole-5-carbonyl]piperidin-3-yl]methoxy]acetic acid;hydrochloride Chemical compound Cl.S1C(NC(=N)N)=NC=C1C(=O)N1CC(COCC(O)=O)CCC1 CMPHFAPVSQDBBX-UHFFFAOYSA-N 0.000 description 1
- ZPQBILFRMMRATD-UHFFFAOYSA-N 2-[[1-[2-(diaminomethylideneamino)-4-methyl-1,3-thiazole-5-carbonyl]pyrrolidin-2-yl]methoxy]acetic acid Chemical compound N1=C(N=C(N)N)SC(C(=O)N2C(CCC2)COCC(O)=O)=C1C ZPQBILFRMMRATD-UHFFFAOYSA-N 0.000 description 1
- FYXKJKMLNKJHHN-UHFFFAOYSA-N 2-[[1-[4-methyl-2-(methylcarbamoylamino)-1,3-thiazole-5-carbonyl]piperidin-3-yl]methoxy]acetic acid Chemical compound S1C(NC(=O)NC)=NC(C)=C1C(=O)N1CC(COCC(O)=O)CCC1 FYXKJKMLNKJHHN-UHFFFAOYSA-N 0.000 description 1
- WOXIHNCFEJTNTG-UHFFFAOYSA-N 3-(carboxymethoxy)piperidine-1-carboxylic acid Chemical compound OC(=O)COC1CCCN(C(O)=O)C1 WOXIHNCFEJTNTG-UHFFFAOYSA-N 0.000 description 1
- LZIBZOMKHDFDMJ-UHFFFAOYSA-N 3-[[1-[2-(diaminomethylideneamino)-1,3-thiazole-4-carbonyl]piperidine-3-carbonyl]amino]propanoic acid Chemical compound S1C(NC(=N)N)=NC(C(=O)N2CC(CCC2)C(=O)NCCC(O)=O)=C1 LZIBZOMKHDFDMJ-UHFFFAOYSA-N 0.000 description 1
- AIDSDCMOFPVYAH-UHFFFAOYSA-N 3-[[1-[2-(diaminomethylideneamino)-4-methyl-1,3-thiazole-5-carbonyl]piperidine-3-carbonyl]amino]-3-phenylpropanoic acid Chemical compound N1=C(NC(N)=N)SC(C(=O)N2CC(CCC2)C(=O)NC(CC(O)=O)C=2C=CC=CC=2)=C1C AIDSDCMOFPVYAH-UHFFFAOYSA-N 0.000 description 1
- MAKBFOGKAZHLCS-UHFFFAOYSA-N 3-[[1-[2-(diaminomethylideneamino)-4-methyl-1,3-thiazole-5-carbonyl]piperidine-3-carbonyl]amino]propanoic acid;hydrochloride Chemical compound Cl.N1=C(NC(N)=N)SC(C(=O)N2CC(CCC2)C(=O)NCCC(O)=O)=C1C MAKBFOGKAZHLCS-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- PRRZDZJYSJLDBS-UHFFFAOYSA-N 3-bromo-2-oxopropanoic acid Chemical compound OC(=O)C(=O)CBr PRRZDZJYSJLDBS-UHFFFAOYSA-N 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- YCORPOVSMZYFCG-UHFFFAOYSA-N CCC1COCCN1CC1=CC=CC=C1 Chemical compound CCC1COCCN1CC1=CC=CC=C1 YCORPOVSMZYFCG-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- GKKZMYDNDDMXSE-UHFFFAOYSA-N Ethyl 3-oxo-3-phenylpropanoate Chemical compound CCOC(=O)CC(=O)C1=CC=CC=C1 GKKZMYDNDDMXSE-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
- GHAZCVNUKKZTLG-UHFFFAOYSA-N N-ethyl-succinimide Natural products CCN1C(=O)CCC1=O GHAZCVNUKKZTLG-UHFFFAOYSA-N 0.000 description 1
- HDFGOPSGAURCEO-UHFFFAOYSA-N N-ethylmaleimide Chemical compound CCN1C(=O)C=CC1=O HDFGOPSGAURCEO-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-N PYRUVIC-ACID Natural products CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 102000002938 Thrombospondin Human genes 0.000 description 1
- 108060008245 Thrombospondin Proteins 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Natural products NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 1
- ZTOJFFHGPLIVKC-CLFAGFIQSA-N abts Chemical compound S/1C2=CC(S(O)(=O)=O)=CC=C2N(CC)C\1=N\N=C1/SC2=CC(S(O)(=O)=O)=CC=C2N1CC ZTOJFFHGPLIVKC-CLFAGFIQSA-N 0.000 description 1
- YBCVMFKXIKNREZ-UHFFFAOYSA-N acoh acetic acid Chemical compound CC(O)=O.CC(O)=O YBCVMFKXIKNREZ-UHFFFAOYSA-N 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 150000001340 alkali metals Chemical class 0.000 description 1
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000005210 alkyl ammonium group Chemical group 0.000 description 1
- 150000001414 amino alcohols Chemical class 0.000 description 1
- UMGDCJDMYOKAJW-UHFFFAOYSA-N aminothiocarboxamide Natural products NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 210000001772 blood platelet Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- AJSHDAOMUKXVDC-UHFFFAOYSA-N butan-1-amine;sulfuric acid Chemical compound CCCC[NH3+].OS([O-])(=O)=O AJSHDAOMUKXVDC-UHFFFAOYSA-N 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- OKGXJRGLYVRVNE-UHFFFAOYSA-N diaminomethylidenethiourea Chemical compound NC(N)=NC(N)=S OKGXJRGLYVRVNE-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- UXGNZZKBCMGWAZ-UHFFFAOYSA-N dimethylformamide dmf Chemical compound CN(C)C=O.CN(C)C=O UXGNZZKBCMGWAZ-UHFFFAOYSA-N 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 125000004185 ester group Chemical group 0.000 description 1
- OCLXJTCGWSSVOE-UHFFFAOYSA-N ethanol etoh Chemical compound CCO.CCO OCLXJTCGWSSVOE-UHFFFAOYSA-N 0.000 description 1
- LJQKCYFTNDAAPC-UHFFFAOYSA-N ethanol;ethyl acetate Chemical compound CCO.CCOC(C)=O LJQKCYFTNDAAPC-UHFFFAOYSA-N 0.000 description 1
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 1
- AZLIZACAECRSGQ-UHFFFAOYSA-N ethyl 2-(diaminomethylideneamino)-1,3-thiazole-5-carboxylate Chemical compound CCOC(=O)C1=CN=C(NC(N)=N)S1 AZLIZACAECRSGQ-UHFFFAOYSA-N 0.000 description 1
- UJAWNRHHRGYVGO-LLVKDONJSA-N ethyl 2-[[(3r)-1-[2-(diaminomethylideneamino)-4-methyl-1,3-thiazole-5-carbonyl]piperidin-3-yl]methoxy]acetate Chemical compound C1[C@H](COCC(=O)OCC)CCCN1C(=O)C1=C(C)N=C(N=C(N)N)S1 UJAWNRHHRGYVGO-LLVKDONJSA-N 0.000 description 1
- UJAWNRHHRGYVGO-NSHDSACASA-N ethyl 2-[[(3s)-1-[2-(diaminomethylideneamino)-4-methyl-1,3-thiazole-5-carbonyl]piperidin-3-yl]methoxy]acetate Chemical compound C1[C@@H](COCC(=O)OCC)CCCN1C(=O)C1=C(C)N=C(N=C(N)N)S1 UJAWNRHHRGYVGO-NSHDSACASA-N 0.000 description 1
- QJEORCCIHZPQKQ-UHFFFAOYSA-N ethyl 2-[[1-[2-(diaminomethylideneamino)-1,3-thiazole-5-carbonyl]piperidin-3-yl]methoxy]acetate Chemical compound C1C(COCC(=O)OCC)CCCN1C(=O)C1=CN=C(NC(N)=N)S1 QJEORCCIHZPQKQ-UHFFFAOYSA-N 0.000 description 1
- WZHUPCREDVWLKC-UHFFFAOYSA-N ethyl 2-amino-4-methyl-1,3-thiazole-5-carboxylate Chemical compound CCOC(=O)C=1SC(N)=NC=1C WZHUPCREDVWLKC-UHFFFAOYSA-N 0.000 description 1
- RDULEYWUGKOCMR-UHFFFAOYSA-N ethyl 2-chloro-3-oxobutanoate Chemical compound CCOC(=O)C(Cl)C(C)=O RDULEYWUGKOCMR-UHFFFAOYSA-N 0.000 description 1
- NUWRDXMXYDWUAN-UHFFFAOYSA-N ethyl 3-amino-3-phenylpropanoate Chemical compound CCOC(=O)CC(N)C1=CC=CC=C1 NUWRDXMXYDWUAN-UHFFFAOYSA-N 0.000 description 1
- VICYTAYPKBLQFB-UHFFFAOYSA-N ethyl 3-bromo-2-oxopropanoate Chemical compound CCOC(=O)C(=O)CBr VICYTAYPKBLQFB-UHFFFAOYSA-N 0.000 description 1
- GVCATXOPLRJXSQ-UHFFFAOYSA-N ethyl 4-cyclopentyl-2-(diaminomethylideneamino)-1,3-thiazole-5-carboxylate Chemical compound S1C(NC(N)=N)=NC(C2CCCC2)=C1C(=O)OCC GVCATXOPLRJXSQ-UHFFFAOYSA-N 0.000 description 1
- VNUOWLZIQBNXQW-UHFFFAOYSA-N ethyl 4-cyclopentyl-2-(diaminomethylideneamino)-1,3-thiazole-5-carboxylate;hydrobromide Chemical compound Br.S1C(NC(N)=N)=NC(C2CCCC2)=C1C(=O)OCC VNUOWLZIQBNXQW-UHFFFAOYSA-N 0.000 description 1
- AFIBNEJBLRTYBI-UHFFFAOYSA-N ethyl 4-methyl-2-(methylcarbamoylamino)-1,3-thiazole-5-carboxylate Chemical compound CCOC(=O)C=1SC(NC(=O)NC)=NC=1C AFIBNEJBLRTYBI-UHFFFAOYSA-N 0.000 description 1
- YWGLHEUOQVNVHG-UHFFFAOYSA-N ethyl 4-tert-butyl-2-(diaminomethylideneamino)-1,3-thiazole-5-carboxylate Chemical compound CCOC(=O)C=1SC(NC(N)=N)=NC=1C(C)(C)C YWGLHEUOQVNVHG-UHFFFAOYSA-N 0.000 description 1
- LNEDHPNHNIKOCE-UHFFFAOYSA-N ethyl 4-tert-butyl-2-(diaminomethylideneamino)-1,3-thiazole-5-carboxylate;hydrobromide Chemical compound Br.CCOC(=O)C=1SC(NC(N)=N)=NC=1C(C)(C)C LNEDHPNHNIKOCE-UHFFFAOYSA-N 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000026030 halogenation Effects 0.000 description 1
- 238000005658 halogenation reaction Methods 0.000 description 1
- 125000003187 heptyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000000623 heterocyclic group Chemical group 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229940106780 human fibrinogen Drugs 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-M hydroxide Chemical compound [OH-] XLYOFNOQVPJJNP-UHFFFAOYSA-M 0.000 description 1
- 239000005457 ice water Substances 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 239000012442 inert solvent Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000002198 insoluble material Substances 0.000 description 1
- 229960004903 invert sugar Drugs 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- 230000000873 masking effect Effects 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- BCVXHSPFUWZLGQ-UHFFFAOYSA-N mecn acetonitrile Chemical compound CC#N.CC#N BCVXHSPFUWZLGQ-UHFFFAOYSA-N 0.000 description 1
- COTNUBDHGSIOTA-UHFFFAOYSA-N meoh methanol Chemical compound OC.OC COTNUBDHGSIOTA-UHFFFAOYSA-N 0.000 description 1
- 125000006431 methyl cyclopropyl group Chemical group 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 125000002347 octyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000004483 piperidin-3-yl group Chemical group N1CC(CCC1)* 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- CHKVPAROMQMJNQ-UHFFFAOYSA-M potassium bisulfate Chemical compound [K+].OS([O-])(=O)=O CHKVPAROMQMJNQ-UHFFFAOYSA-M 0.000 description 1
- OTYBMLCTZGSZBG-UHFFFAOYSA-L potassium sulfate Chemical compound [K+].[K+].[O-]S([O-])(=O)=O OTYBMLCTZGSZBG-UHFFFAOYSA-L 0.000 description 1
- 229910052939 potassium sulfate Inorganic materials 0.000 description 1
- 235000011151 potassium sulphates Nutrition 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000007363 ring formation reaction Methods 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 210000000329 smooth muscle myocyte Anatomy 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- VOXKEGVSYZTFES-UHFFFAOYSA-M sodium;2-(diaminomethylideneamino)-1,3-thiazole-4-carboxylate Chemical compound [Na+].NC(N)=NC1=NC(C([O-])=O)=CS1 VOXKEGVSYZTFES-UHFFFAOYSA-M 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000001384 succinic acid Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 1
- BFFLLBPMZCIGRM-QMMMGPOBSA-N tert-butyl (2s)-2-(hydroxymethyl)pyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC[C@H]1CO BFFLLBPMZCIGRM-QMMMGPOBSA-N 0.000 description 1
- OJCLHERKFHHUTB-SECBINFHSA-N tert-butyl (3r)-3-(hydroxymethyl)piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC[C@@H](CO)C1 OJCLHERKFHHUTB-SECBINFHSA-N 0.000 description 1
- OJCLHERKFHHUTB-VIFPVBQESA-N tert-butyl (3s)-3-(hydroxymethyl)piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC[C@H](CO)C1 OJCLHERKFHHUTB-VIFPVBQESA-N 0.000 description 1
- TXQWZKBWJLVXFK-UHFFFAOYSA-N tert-butyl 2-[1-[2-(diaminomethylideneamino)-4-methyl-1,3-thiazole-5-carbonyl]piperidin-4-yl]oxyacetate Chemical compound N1=C(NC(N)=N)SC(C(=O)N2CCC(CC2)OCC(=O)OC(C)(C)C)=C1C TXQWZKBWJLVXFK-UHFFFAOYSA-N 0.000 description 1
- LPWLXVDDRMCHNL-LLVKDONJSA-N tert-butyl 2-[[(3r)-1-[2-(diaminomethylideneamino)-4-methyl-1,3-thiazole-5-carbonyl]pyrrolidin-3-yl]methoxy]acetate Chemical compound N1=C(NC(N)=N)SC(C(=O)N2C[C@H](COCC(=O)OC(C)(C)C)CC2)=C1C LPWLXVDDRMCHNL-LLVKDONJSA-N 0.000 description 1
- BNWCETAHAJSBFG-UHFFFAOYSA-N tert-butyl 2-bromoacetate Chemical compound CC(C)(C)OC(=O)CBr BNWCETAHAJSBFG-UHFFFAOYSA-N 0.000 description 1
- PCOKVBQRZCEGTJ-UHFFFAOYSA-N tert-butyl 2-piperidin-4-yloxyacetate Chemical compound CC(C)(C)OC(=O)COC1CCNCC1 PCOKVBQRZCEGTJ-UHFFFAOYSA-N 0.000 description 1
- RNIPKKXLPCRCPS-UHFFFAOYSA-N tert-butyl 3-[(3-ethoxy-3-oxo-1-phenylpropyl)carbamoyl]piperidine-1-carboxylate Chemical compound C=1C=CC=CC=1C(CC(=O)OCC)NC(=O)C1CCCN(C(=O)OC(C)(C)C)C1 RNIPKKXLPCRCPS-UHFFFAOYSA-N 0.000 description 1
- UIJXHKXIOCDSEB-UHFFFAOYSA-N tert-butyl 3-hydroxypiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCC(O)C1 UIJXHKXIOCDSEB-UHFFFAOYSA-N 0.000 description 1
- WZDCSGDAEYOHIA-UHFFFAOYSA-N tert-butyl 4-[(2-ethoxy-2-oxoethoxy)methyl]piperidine-1-carboxylate Chemical compound CCOC(=O)COCC1CCN(C(=O)OC(C)(C)C)CC1 WZDCSGDAEYOHIA-UHFFFAOYSA-N 0.000 description 1
- JRMUNVKIHCOMHV-UHFFFAOYSA-M tetrabutylammonium bromide Chemical compound [Br-].CCCC[N+](CCCC)(CCCC)CCCC JRMUNVKIHCOMHV-UHFFFAOYSA-M 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- QEMXHQIAXOOASZ-UHFFFAOYSA-N tetramethylammonium Chemical class C[N+](C)(C)C QEMXHQIAXOOASZ-UHFFFAOYSA-N 0.000 description 1
- WROMPOXWARCANT-UHFFFAOYSA-N tfa trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F.OC(=O)C(F)(F)F WROMPOXWARCANT-UHFFFAOYSA-N 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000001665 trituration Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/48—Acylated amino or imino radicals by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof, e.g. carbonylguanidines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Hematology (AREA)
- Communicable Diseases (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Nutrition Science (AREA)
- Obesity (AREA)
- Virology (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP98100007 | 1998-01-02 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO986160D0 NO986160D0 (no) | 1998-12-28 |
| NO986160L NO986160L (no) | 1999-07-05 |
| NO312134B1 true NO312134B1 (no) | 2002-03-25 |
Family
ID=8231230
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO19986160A NO312134B1 (no) | 1998-01-02 | 1998-12-28 | Tiazolderivater, fremgangsmåte for fremstilling og anvendelse av dem, farmasöytisk preparat inneholdende dem og mellomprodukteri fremstillingen |
Country Status (29)
| Country | Link |
|---|---|
| US (1) | US6001855A (es) |
| JP (1) | JP3154982B2 (es) |
| KR (1) | KR100312900B1 (es) |
| CN (1) | CN1098849C (es) |
| AR (1) | AR014211A1 (es) |
| AT (1) | ATE217621T1 (es) |
| AU (1) | AU718659B2 (es) |
| BR (1) | BR9805750A (es) |
| CA (1) | CA2257322C (es) |
| CO (1) | CO4990935A1 (es) |
| DE (1) | DE69805392T2 (es) |
| DK (1) | DK0928793T3 (es) |
| ES (1) | ES2176895T3 (es) |
| HK (1) | HK1021733A1 (es) |
| HR (1) | HRP980644B1 (es) |
| HU (1) | HUP9803041A3 (es) |
| ID (1) | ID21878A (es) |
| IL (1) | IL127784A (es) |
| MA (1) | MA26590A1 (es) |
| NO (1) | NO312134B1 (es) |
| PE (1) | PE20000116A1 (es) |
| PL (1) | PL330620A1 (es) |
| PT (1) | PT928793E (es) |
| RU (1) | RU2166503C2 (es) |
| SG (1) | SG72911A1 (es) |
| TR (1) | TR199802766A2 (es) |
| UY (1) | UY25335A1 (es) |
| YU (1) | YU60998A (es) |
| ZA (1) | ZA9811923B (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4517454B2 (ja) * | 2000-06-01 | 2010-08-04 | 宇部興産株式会社 | ４−（１−フルオロエチル）チアゾール−５−カルボン酸アミド誘導体及び農園芸用の有害生物防除剤 |
| US6451821B1 (en) * | 2000-06-09 | 2002-09-17 | Aventis Pharma S.A. | Use of 2-aminothiazoline derivatives as inhibitors of inducible no-synthase |
| US6420566B2 (en) * | 2000-06-09 | 2002-07-16 | Aventis Pharma S.A. | Pharmaceutical compositions containing a 4, 5-dihydro-1, 3-thiazol-2-ylamine derivative, novel derivatives and preparation thereof |
| KR20180088713A (ko) * | 2015-12-04 | 2018-08-06 | 얀센 바이오테크 인코포레이티드 | 전구 세포를 사용한 망막 변성의 치료 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2138803B (en) * | 1983-04-26 | 1986-06-18 | Shionogi & Co | 2-guanidino-4-hydroxymethylthiazole and derivatives thereof |
| IL95548A0 (en) * | 1989-09-15 | 1991-06-30 | Fujisawa Pharmaceutical Co | Thiazole derivatives,processes for the preparation thereof and pharmaceutical composition containing the same |
| TW201303B (es) * | 1990-07-05 | 1993-03-01 | Hoffmann La Roche | |
| ES2161373T3 (es) * | 1995-08-30 | 2001-12-01 | Searle & Co | Derivados de meta-guanidina, urea, tiourea o acido azaciclico-aminobenzoico como antagonistas de integrinas. |
| AU713676B2 (en) * | 1996-01-16 | 1999-12-09 | Merck & Co., Inc. | Integrin receptor antagonists |
| EP0986551B1 (en) * | 1997-05-30 | 2006-08-02 | Takeda Pharmaceutical Company Limited | Sulfonamide derivatives, their production and use |
-
1998
- 1998-12-22 US US09/218,200 patent/US6001855A/en not_active Expired - Fee Related
- 1998-12-28 NO NO19986160A patent/NO312134B1/no unknown
- 1998-12-29 AR ARP980106722A patent/AR014211A1/es not_active Application Discontinuation
- 1998-12-29 YU YU60998A patent/YU60998A/sh unknown
- 1998-12-29 ZA ZA9811923A patent/ZA9811923B/xx unknown
- 1998-12-29 IL IL12778498A patent/IL127784A/en not_active IP Right Cessation
- 1998-12-29 HR HR980644A patent/HRP980644B1/xx not_active IP Right Cessation
- 1998-12-29 PE PE1998001292A patent/PE20000116A1/es not_active Application Discontinuation
- 1998-12-30 PL PL98330620A patent/PL330620A1/xx not_active Application Discontinuation
- 1998-12-30 KR KR1019980061644A patent/KR100312900B1/ko not_active IP Right Cessation
- 1998-12-30 AU AU96145/98A patent/AU718659B2/en not_active Ceased
- 1998-12-30 MA MA25410A patent/MA26590A1/fr unknown
- 1998-12-30 DE DE69805392T patent/DE69805392T2/de not_active Expired - Fee Related
- 1998-12-30 DK DK98124819T patent/DK0928793T3/da active
- 1998-12-30 CA CA002257322A patent/CA2257322C/en not_active Expired - Fee Related
- 1998-12-30 TR TR1998/02766A patent/TR199802766A2/xx unknown
- 1998-12-30 CO CO98077474A patent/CO4990935A1/es unknown
- 1998-12-30 ES ES98124819T patent/ES2176895T3/es not_active Expired - Lifetime
- 1998-12-30 PT PT98124819T patent/PT928793E/pt unknown
- 1998-12-30 SG SG1998005979A patent/SG72911A1/en unknown
- 1998-12-30 HU HU9803041A patent/HUP9803041A3/hu unknown
- 1998-12-30 AT AT98124819T patent/ATE217621T1/de not_active IP Right Cessation
- 1998-12-31 BR BR9805750-2A patent/BR9805750A/pt not_active Application Discontinuation
- 1998-12-31 CN CN98125981A patent/CN1098849C/zh not_active Expired - Fee Related
- 1998-12-31 UY UY25335A patent/UY25335A1/es not_active IP Right Cessation
-
1999
- 1999-01-04 ID IDP990002A patent/ID21878A/id unknown
- 1999-01-04 JP JP00020699A patent/JP3154982B2/ja not_active Expired - Fee Related
- 1999-01-05 RU RU99100205/04A patent/RU2166503C2/ru not_active IP Right Cessation
-
2000
- 2000-01-31 HK HK00100585A patent/HK1021733A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0928790B1 (en) | Thiazole derivatives | |
| ES2367267T3 (es) | Ciclopropil-(2,3-dimetilbencil)amida del ácido 7-(4-(2-(2,6-dicloro-4-metilfenoxi)etoxi)fenil)-3,9-diazabiciclo(3.3.1)non-6-eno-6-carboxílico como inhibidor de renina para el tratamiento de la hipertensión. | |
| US6344562B1 (en) | Thiazole derivatives | |
| EP0928793B1 (en) | Thiazole derivatives | |
| NO312134B1 (no) | Tiazolderivater, fremgangsmåte for fremstilling og anvendelse av dem, farmasöytisk preparat inneholdende dem og mellomprodukteri fremstillingen | |
| KR100469219B1 (ko) | 티아졸-유도체 | |
| CZ437198A3 (cs) | Deriváty thiazolu | |
| MXPA99000216A (es) | Derivados de tiazol | |
| CZ437098A3 (cs) | Deriváty thiazolu |